Mean apparent diffusion coefficient in a single slice may predict tumor response to whole-brain radiation therapy in non-small-cell lung cancer patients with brain metastases

被引:3
|
作者
Zhao, Lihao [1 ]
Zhao, Mengjing [2 ]
Liu, Jinjin [2 ]
Yang, Han [1 ]
Zhou, Xiaojun [2 ]
Wen, Caiyun [2 ]
Li, Gang [1 ]
Duan, Yuxia [2 ]
机构
[1] Wenzhou Med Univ, Dept Chemoradiat Oncol, Affiliated Hosp 1, 2 Fuxue Lane, Wenzhou 325000, Peoples R China
[2] Wenzhou Med Univ, Dept Radiol, Affiliated Hosp 1, South Baixiang St, Wenzhou 325000, Peoples R China
关键词
Diffusion magnetic resonance imaging; Radiotherapy; Brain neoplasms; Carcinoma; non-small-cell lung; Treatment outcome; STEREOTACTIC RADIOSURGERY; SUPPORTIVE CARE; WEIGHTED MRI; RADIOTHERAPY; CHEMORADIOTHERAPY; TOMOGRAPHY; MANAGEMENT; SURVIVAL;
D O I
10.1007/s00330-020-07584-0
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives This study aimed to access the performance of apparent diffusion coefficient (ADC) as a predictor for treatment response to whole-brain radiotherapy (WBRT) in patients with brain metastases (BMs) from non-small-cell lung cancer (NSCLC). Methods A retrospective analysis was conducted of 102 NSCLC patients with BMs who underwent WBRT between 2012 and 2016. Diffusion-weighted MRI were performed pre-WBRT and within 12 weeks after WBRT started. Mean single-plane ADC value of ROIs was evaluated by two radiologists blinded to results of each other. The treatment response rate, intracranial progression-free survival (PFS), and overall survival (OS) were analyzed based on the ADC value and Delta ADC respectively. At last, we used COX and logistic regression to do the multivariate analysis. Results There was good inter-observer agreement of mean ADC value pre-WBRT, post-WBRT, and Delta ADC between the 2 radiologists (Pearson correlation 0.915 [pre-WBRT], 0.950 [post-WBRT], 0.937 [Delta ADC], p < 0.001, for each one). High mean ADC value were related with better response rate (72.2% vs 37.5%, p = 0.001) and iPFS (7.6 vs 6.4 months, p = 0.031). High Delta ADC were related with better response rate (73.6% vs 36.7%, p < 0.001). Multivariate analysis shows that histopathology, BMs number, high ADC value pre-WBRT, and high Delta ADC post-WBRT were related to better treatment response of WBRT, and KPS, BMs number, and low ADC value pre-WBRT increased the risk of developing intracranial relapse. ConclusionsThe mean single-plane ADC value pre-WBRT and Delta ADC post-WBRT were potential predictor for intracranial tumor response to WBRT in NSCLC patients with brain metastases. Key Points ADC value is a potential predictor of intracranial treatment response to WBRT in NSCLC patients with brain metastases. Higher mean ADC value pre-WBRT and.ADC post-WBRT of brain metastases were related to better intracranial tumor response. Prediction of response before WBRT using ADC value can help oncologists to make better therapy plans and avoid missing opportunities for rescue therapy.
引用
收藏
页码:5565 / 5575
页数:11
相关论文
共 50 条
  • [11] Whole-brain radiation therapy in breast cancer patients with brain metastases
    Chargari, Cyrus
    Campana, Francois
    Pierga, Jean-Yves
    Vedrine, Lionel
    Ricard, Damien
    Le Moulec, Sylvestre
    Fourquet, Alain
    Kirova, Youlia M.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (11) : 632 - 640
  • [12] Additional radiation boost to whole brain radiation therapy may improve the survival of patients with brain metastases in small cell lung cancer
    Han Sun
    Liming Xu
    Youyou Wang
    Junhua Zhao
    Kunpeng Xu
    Jing Qi
    Zhiyong Yuan
    Lujun Zhao
    Ping Wang
    Radiation Oncology, 13
  • [13] Additional radiation boost to whole brain radiation therapy may improve the survival of patients with brain metastases in small cell lung cancer
    Sun, Han
    Xu, Liming
    Wang, Youyou
    Zhao, Junhua
    Xu, Kunpeng
    Qi, Jing
    Yuan, Zhiyong
    Zhao, Lujun
    Wang, Ping
    RADIATION ONCOLOGY, 2018, 13
  • [14] Quality of life and efficacy of temozolomide combined with whole-brain radiotherapy in patients with brain metastases from non-small-cell lung cancer
    Lv, Yajuan
    Zhang, Jiandong
    Liu, Zhen
    Liang, Ning
    Tian, Yuan
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (01) : 70 - 74
  • [15] Concurrent whole-brain radiation therapy combined with chemotherapy consisted of carboplatin and paclitaxel in non-small cell lung cancer patients with brain metastases
    Kogure, Y
    Takahashi, T
    Ueda, S
    Ebisawa, M
    Asai, G
    Harada, H
    Yamamoto, N
    LUNG CANCER, 2005, 49 : S253 - S253
  • [16] Phase II Study of Erlotinib with Concurrent Whole-brain Radiation Therapy for Patients with Brain Metastases from Non-small Cell Lung Cancer
    Welsh, J. W.
    Kim, E.
    Amini, A.
    Allen, P.
    Chang, J.
    Komaki, R.
    Nguyen, N.
    Holt, J.
    Erdman, D.
    Stea, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S136 - S136
  • [17] PHASE II STUDY OF ERLOTINIB WITH CONCURRENT WHOLE-BRAIN RADIATION THERAPY FOR PATIENTS WITH BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER
    Welsh, James
    Amini, Arya
    Kim, Edward
    Allen, Pamela K.
    Chang, Joe Y.
    Garland, Linda
    Komaki, Ritsuko
    Stea, Baldassarre
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1587 - S1587
  • [18] Outcomes in Patients Treated With Whole-Brain Radiation Therapy Versus Stereotactic Radiosurgery for Brain Metastases Secondary to Non-Small Cell Lung Cancer
    Henson, C.
    Arain, A.
    Herman, T.
    Ahmad, S.
    Matthiesen, C. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S693 - S693
  • [19] Erlotinib plus concurrent whole-brain radiation therapy for non-small cell lung cancers patients with multiple brain metastases
    Ulahannan, Danny
    Lee, Siow-Ming
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (02) : 208 - 211
  • [20] A phase I study of cediranib plus whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer
    Eichler, A. F.
    Shih, H. A.
    Sequist, L. V.
    Wen, P. Y.
    Jain, R. K.
    Sorensen, A. G.
    Batchelor, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)